nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—LRP5—osteoporosis	0.0349	0.0723	CbGpPWpGaD
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—LRP6—osteoporosis	0.0334	0.0692	CbGpPWpGaD
Fluocinonide—SMO—Signaling events mediated by the Hedgehog family—PTHLH—osteoporosis	0.0317	0.0657	CbGpPWpGaD
Fluocinonide—SMO—Class B/2 (Secretin family receptors)—PTH1R—osteoporosis	0.0252	0.0521	CbGpPWpGaD
Fluocinonide—SMO—Class B/2 (Secretin family receptors)—CALCR—osteoporosis	0.0252	0.0521	CbGpPWpGaD
Fluocinonide—Allergic contact dermatitis—Estradiol—osteoporosis	0.0161	0.0312	CcSEcCtD
Fluocinonide—SMO—Class B/2 (Secretin family receptors)—PTH—osteoporosis	0.0132	0.0274	CbGpPWpGaD
Fluocinonide—SMO—Class B/2 (Secretin family receptors)—WNT1—osteoporosis	0.0121	0.0251	CbGpPWpGaD
Fluocinonide—Application site reaction—Estradiol—osteoporosis	0.012	0.0233	CcSEcCtD
Fluocinonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—RAP1A—osteoporosis	0.0111	0.023	CbGpPWpGaD
Fluocinonide—SMO—Signaling by Hedgehog—P4HB—osteoporosis	0.011	0.0228	CbGpPWpGaD
Fluocinonide—NR3C1—Signaling events mediated by HDAC Class II—TUBA1B—osteoporosis	0.011	0.0228	CbGpPWpGaD
Fluocinonide—SMO—Class B/2 (Secretin family receptors)—PTHLH—osteoporosis	0.0109	0.0227	CbGpPWpGaD
Fluocinonide—SMO—Class B/2 (Secretin family receptors)—CALCA—osteoporosis	0.00964	0.02	CbGpPWpGaD
Fluocinonide—SMO—Hedgehog 'off' state—PSMA5—osteoporosis	0.0094	0.0195	CbGpPWpGaD
Fluocinonide—SMO—Hedgehog 'off' state—PSMA2—osteoporosis	0.0094	0.0195	CbGpPWpGaD
Fluocinonide—Eruption—Estradiol—osteoporosis	0.00917	0.0177	CcSEcCtD
Fluocinonide—Swelling—Ibandronate—osteoporosis	0.00842	0.0163	CcSEcCtD
Fluocinonide—SMO—Signaling by Hedgehog—PSMA5—osteoporosis	0.00839	0.0174	CbGpPWpGaD
Fluocinonide—SMO—Signaling by Hedgehog—PSMA2—osteoporosis	0.00839	0.0174	CbGpPWpGaD
Fluocinonide—Dry skin—Alendronate—osteoporosis	0.00699	0.0135	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	0.00692	0.0143	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—PTH1R—osteoporosis	0.00688	0.0142	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—CALCR—osteoporosis	0.00688	0.0142	CbGpPWpGaD
Fluocinonide—Nasopharyngitis—Ibandronate—osteoporosis	0.00664	0.0128	CcSEcCtD
Fluocinonide—Swelling—Pamidronate—osteoporosis	0.0066	0.0128	CcSEcCtD
Fluocinonide—Nasopharyngitis—Calcitriol—osteoporosis	0.0065	0.0126	CcSEcCtD
Fluocinonide—SMO—Hedgehog 'off' state—ADCY5—osteoporosis	0.00623	0.0129	CbGpPWpGaD
Fluocinonide—Hyperglycaemia—Estropipate—osteoporosis	0.00604	0.0117	CcSEcCtD
Fluocinonide—Swelling—Zoledronate—osteoporosis	0.00602	0.0116	CcSEcCtD
Fluocinonide—Swelling—Conjugated Estrogens—osteoporosis	0.0058	0.0112	CcSEcCtD
Fluocinonide—Pain—Calcium Acetate—osteoporosis	0.00573	0.0111	CcSEcCtD
Fluocinonide—Dermatitis contact—Estradiol—osteoporosis	0.00558	0.0108	CcSEcCtD
Fluocinonide—SMO—Signaling by Hedgehog—ADCY5—osteoporosis	0.00556	0.0115	CbGpPWpGaD
Fluocinonide—Nasopharyngitis—Risedronate—osteoporosis	0.00547	0.0106	CcSEcCtD
Fluocinonide—Erythema—Etidronic acid—osteoporosis	0.00539	0.0104	CcSEcCtD
Fluocinonide—Skin exfoliation—Estradiol—osteoporosis	0.00539	0.0104	CcSEcCtD
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—MYC—osteoporosis	0.00522	0.0108	CbGpPWpGaD
Fluocinonide—Nasopharyngitis—Pamidronate—osteoporosis	0.0052	0.0101	CcSEcCtD
Fluocinonide—Pain—Ergocalciferol—osteoporosis	0.00506	0.00979	CcSEcCtD
Fluocinonide—Hypersensitivity—Calcium Acetate—osteoporosis	0.00494	0.00955	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	0.00493	0.0102	CbGpPWpGaD
Fluocinonide—Immune system disorder—Estropipate—osteoporosis	0.00484	0.00936	CcSEcCtD
Fluocinonide—Nasopharyngitis—Zoledronate—osteoporosis	0.00475	0.00919	CcSEcCtD
Fluocinonide—Pruritus—Calcium Acetate—osteoporosis	0.00474	0.00917	CcSEcCtD
Fluocinonide—Erythema—Estropipate—osteoporosis	0.00466	0.00902	CcSEcCtD
Fluocinonide—Swelling—Estradiol—osteoporosis	0.00464	0.00898	CcSEcCtD
Fluocinonide—Immune system disorder—Ibandronate—osteoporosis	0.00464	0.00897	CcSEcCtD
Fluocinonide—Erythema—Alendronate—osteoporosis	0.00459	0.00888	CcSEcCtD
Fluocinonide—NR3C1—Transcription factor regulation in adipogenesis—IRS2—osteoporosis	0.00455	0.00943	CbGpPWpGaD
Fluocinonide—NR3C1—Nuclear Receptors—ESR2—osteoporosis	0.00453	0.00938	CbGpPWpGaD
Fluocinonide—Nasal congestion—Estradiol—osteoporosis	0.0045	0.00869	CcSEcCtD
Fluocinonide—Erythema—Ibandronate—osteoporosis	0.00447	0.00865	CcSEcCtD
Fluocinonide—NR3C1—Transcription factor regulation in adipogenesis—LEP—osteoporosis	0.00445	0.00923	CbGpPWpGaD
Fluocinonide—Dizziness—Calcium Acetate—osteoporosis	0.00443	0.00857	CcSEcCtD
Fluocinonide—Erythema—Calcitriol—osteoporosis	0.00438	0.00847	CcSEcCtD
Fluocinonide—Infection—Etidronic acid—osteoporosis	0.00437	0.00845	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—COL1A2—osteoporosis	0.00401	0.0083	CbGpPWpGaD
Fluocinonide—Hyperglycaemia—Conjugated Estrogens—osteoporosis	0.00399	0.00771	CcSEcCtD
Fluocinonide—NR3C1—Transcription factor regulation in adipogenesis—IRS1—osteoporosis	0.00397	0.00823	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Estropipate—osteoporosis	0.00394	0.00762	CcSEcCtD
Fluocinonide—Immune system disorder—Ethinyl Estradiol—osteoporosis	0.00392	0.00758	CcSEcCtD
Fluocinonide—NR3C1—Endoderm Differentiation—DKK1—osteoporosis	0.00387	0.00801	CbGpPWpGaD
Fluocinonide—Immune system disorder—Risedronate—osteoporosis	0.00382	0.00739	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Raloxifene—osteoporosis	0.00382	0.00739	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—NFATC1—osteoporosis	0.00381	0.00789	CbGpPWpGaD
Fluocinonide—Infection—Estropipate—osteoporosis	0.00378	0.00731	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Ibandronate—osteoporosis	0.00378	0.00731	CcSEcCtD
Fluocinonide—Dry skin—Estradiol—osteoporosis	0.00375	0.00726	CcSEcCtD
Fluocinonide—Nervous system disorder—Estropipate—osteoporosis	0.00373	0.00722	CcSEcCtD
Fluocinonide—Infection—Alendronate—osteoporosis	0.00373	0.0072	CcSEcCtD
Fluocinonide—Skin disorder—Estropipate—osteoporosis	0.0037	0.00715	CcSEcCtD
Fluocinonide—Infection—Raloxifene—osteoporosis	0.00366	0.00708	CcSEcCtD
Fluocinonide—Nasopharyngitis—Estradiol—osteoporosis	0.00366	0.00708	CcSEcCtD
Fluocinonide—Immune system disorder—Pamidronate—osteoporosis	0.00364	0.00703	CcSEcCtD
Fluocinonide—Infection—Ibandronate—osteoporosis	0.00363	0.00701	CcSEcCtD
Fluocinonide—Nervous system disorder—Raloxifene—osteoporosis	0.00362	0.00699	CcSEcCtD
Fluocinonide—SMO—GPCR ligand binding—PTH—osteoporosis	0.00361	0.00748	CbGpPWpGaD
Fluocinonide—NR3C1—Nuclear Receptors—VDR—osteoporosis	0.00359	0.00745	CbGpPWpGaD
Fluocinonide—Skin disorder—Raloxifene—osteoporosis	0.00358	0.00692	CcSEcCtD
Fluocinonide—Nervous system disorder—Ibandronate—osteoporosis	0.00358	0.00692	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptor transcription pathway—ESR2—osteoporosis	0.00358	0.00741	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—COL1A2—osteoporosis	0.00357	0.00739	CbGpPWpGaD
Fluocinonide—Skin disorder—Ibandronate—osteoporosis	0.00355	0.00686	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—CALCR—osteoporosis	0.00353	0.00731	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—PTH1R—osteoporosis	0.00353	0.00731	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—CNR2—osteoporosis	0.00352	0.00729	CbGpPWpGaD
Fluocinonide—Erythema—Pamidronate—osteoporosis	0.0035	0.00677	CcSEcCtD
Fluocinonide—Skin disorder—Calcitriol—osteoporosis	0.00347	0.00671	CcSEcCtD
Fluocinonide—NR3C1—Endoderm Differentiation—PTHLH—osteoporosis	0.00337	0.00698	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—NFATC1—osteoporosis	0.00336	0.00695	CbGpPWpGaD
Fluocinonide—Immune system disorder—Zoledronate—osteoporosis	0.00332	0.00642	CcSEcCtD
Fluocinonide—SMO—GPCR ligand binding—WNT1—osteoporosis	0.00331	0.00686	CbGpPWpGaD
Fluocinonide—Pain—Estropipate—osteoporosis	0.00326	0.00629	CcSEcCtD
Fluocinonide—Hypersensitivity—Etidronic acid—osteoporosis	0.00324	0.00627	CcSEcCtD
Fluocinonide—Pain—Alendronate—osteoporosis	0.00321	0.0062	CcSEcCtD
Fluocinonide—Erythema—Zoledronate—osteoporosis	0.0032	0.00619	CcSEcCtD
Fluocinonide—Immune system disorder—Conjugated Estrogens—osteoporosis	0.0032	0.00618	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.0032	0.00618	CcSEcCtD
Fluocinonide—Hyperglycaemia—Estradiol—osteoporosis	0.00319	0.00617	CcSEcCtD
Fluocinonide—Pain—Raloxifene—osteoporosis	0.00315	0.0061	CcSEcCtD
Fluocinonide—Pain—Ibandronate—osteoporosis	0.00312	0.00604	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.00312	0.00603	CcSEcCtD
Fluocinonide—Pruritus—Etidronic acid—osteoporosis	0.00311	0.00602	CcSEcCtD
Fluocinonide—Erythema—Conjugated Estrogens—osteoporosis	0.00308	0.00596	CcSEcCtD
Fluocinonide—Infection—Ethinyl Estradiol—osteoporosis	0.00307	0.00593	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—BGLAP—osteoporosis	0.00306	0.00634	CbGpPWpGaD
Fluocinonide—Pain—Calcitriol—osteoporosis	0.00306	0.00591	CcSEcCtD
Fluocinonide—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.00303	0.00585	CcSEcCtD
Fluocinonide—Skin disorder—Ethinyl Estradiol—osteoporosis	0.003	0.00579	CcSEcCtD
Fluocinonide—SMO—GPCR ligand binding—PTHLH—osteoporosis	0.00299	0.0062	CbGpPWpGaD
Fluocinonide—Infection—Risedronate—osteoporosis	0.00299	0.00578	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	0.00299	0.00619	CbGpPWpGaD
Fluocinonide—Nervous system disorder—Risedronate—osteoporosis	0.00295	0.0057	CcSEcCtD
Fluocinonide—Skin disorder—Risedronate—osteoporosis	0.00292	0.00565	CcSEcCtD
Fluocinonide—Infection—Pamidronate—osteoporosis	0.00284	0.00549	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptor transcription pathway—VDR—osteoporosis	0.00284	0.00588	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Estropipate—osteoporosis	0.0028	0.00542	CcSEcCtD
Fluocinonide—Nervous system disorder—Pamidronate—osteoporosis	0.0028	0.00542	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—MGLL—osteoporosis	0.0028	0.00581	CbGpPWpGaD
Fluocinonide—Rash—Etidronic acid—osteoporosis	0.00277	0.00536	CcSEcCtD
Fluocinonide—Dermatitis—Etidronic acid—osteoporosis	0.00277	0.00536	CcSEcCtD
Fluocinonide—Hypersensitivity—Alendronate—osteoporosis	0.00276	0.00534	CcSEcCtD
Fluocinonide—Headache—Etidronic acid—osteoporosis	0.00276	0.00533	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptors—ESR1—osteoporosis	0.00275	0.00569	CbGpPWpGaD
Fluocinonide—NR3C1—Signaling events mediated by HDAC Class II—ESR1—osteoporosis	0.00275	0.00569	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.00271	0.00523	CcSEcCtD
Fluocinonide—Pruritus—Estropipate—osteoporosis	0.00269	0.00521	CcSEcCtD
Fluocinonide—Hypersensitivity—Ibandronate—osteoporosis	0.00269	0.0052	CcSEcCtD
Fluocinonide—Pruritus—Alendronate—osteoporosis	0.00265	0.00513	CcSEcCtD
Fluocinonide—SMO—GPCR ligand binding—CALCA—osteoporosis	0.00264	0.00546	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Calcitriol—osteoporosis	0.00263	0.00509	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.00261	0.00504	CcSEcCtD
Fluocinonide—Infection—Zoledronate—osteoporosis	0.0026	0.00502	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	0.00259	0.00536	CbGpPWpGaD
Fluocinonide—Pruritus—Ibandronate—osteoporosis	0.00258	0.00499	CcSEcCtD
Fluocinonide—Pain—Risedronate—osteoporosis	0.00257	0.00497	CcSEcCtD
Fluocinonide—Nervous system disorder—Zoledronate—osteoporosis	0.00256	0.00495	CcSEcCtD
Fluocinonide—Immune system disorder—Estradiol—osteoporosis	0.00256	0.00495	CcSEcCtD
Fluocinonide—Skin disorder—Zoledronate—osteoporosis	0.00254	0.00491	CcSEcCtD
Fluocinonide—Pruritus—Calcitriol—osteoporosis	0.00253	0.00489	CcSEcCtD
Fluocinonide—Dizziness—Estropipate—osteoporosis	0.00252	0.00487	CcSEcCtD
Fluocinonide—Infection—Conjugated Estrogens—osteoporosis	0.0025	0.00483	CcSEcCtD
Fluocinonide—Dizziness—Alendronate—osteoporosis	0.00248	0.00479	CcSEcCtD
Fluocinonide—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.00247	0.00477	CcSEcCtD
Fluocinonide—Erythema—Estradiol—osteoporosis	0.00247	0.00477	CcSEcCtD
Fluocinonide—Pain—Pamidronate—osteoporosis	0.00245	0.00473	CcSEcCtD
Fluocinonide—Skin disorder—Conjugated Estrogens—osteoporosis	0.00244	0.00472	CcSEcCtD
Fluocinonide—Dizziness—Raloxifene—osteoporosis	0.00244	0.00471	CcSEcCtD
Fluocinonide—Dizziness—Ibandronate—osteoporosis	0.00241	0.00467	CcSEcCtD
Fluocinonide—Rash—Estropipate—osteoporosis	0.0024	0.00464	CcSEcCtD
Fluocinonide—Dermatitis—Estropipate—osteoporosis	0.0024	0.00464	CcSEcCtD
Fluocinonide—Headache—Estropipate—osteoporosis	0.00238	0.00461	CcSEcCtD
Fluocinonide—Rash—Alendronate—osteoporosis	0.00236	0.00457	CcSEcCtD
Fluocinonide—Dermatitis—Alendronate—osteoporosis	0.00236	0.00457	CcSEcCtD
Fluocinonide—Headache—Alendronate—osteoporosis	0.00235	0.00454	CcSEcCtD
Fluocinonide—Rash—Raloxifene—osteoporosis	0.00233	0.00449	CcSEcCtD
Fluocinonide—Dermatitis—Raloxifene—osteoporosis	0.00232	0.00449	CcSEcCtD
Fluocinonide—Headache—Raloxifene—osteoporosis	0.00231	0.00447	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—SOST—osteoporosis	0.00231	0.00478	CbGpPWpGaD
Fluocinonide—Rash—Ibandronate—osteoporosis	0.0023	0.00445	CcSEcCtD
Fluocinonide—Dermatitis—Ibandronate—osteoporosis	0.0023	0.00445	CcSEcCtD
Fluocinonide—Headache—Ibandronate—osteoporosis	0.00229	0.00442	CcSEcCtD
Fluocinonide—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.00227	0.0044	CcSEcCtD
Fluocinonide—Rash—Calcitriol—osteoporosis	0.00225	0.00436	CcSEcCtD
Fluocinonide—Dermatitis—Calcitriol—osteoporosis	0.00225	0.00435	CcSEcCtD
Fluocinonide—Headache—Calcitriol—osteoporosis	0.00224	0.00433	CcSEcCtD
Fluocinonide—Pain—Zoledronate—osteoporosis	0.00223	0.00432	CcSEcCtD
Fluocinonide—NR3C1—Adipogenesis—WNT1—osteoporosis	0.00222	0.00459	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Risedronate—osteoporosis	0.00222	0.00429	CcSEcCtD
Fluocinonide—Pruritus—Ethinyl Estradiol—osteoporosis	0.00218	0.00422	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptor transcription pathway—ESR1—osteoporosis	0.00217	0.0045	CbGpPWpGaD
Fluocinonide—Pain—Conjugated Estrogens—osteoporosis	0.00215	0.00416	CcSEcCtD
Fluocinonide—Pruritus—Risedronate—osteoporosis	0.00213	0.00412	CcSEcCtD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—GAPDH—osteoporosis	0.00211	0.00437	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Pamidronate—osteoporosis	0.00211	0.00407	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.00209	0.00403	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—PTH1R—osteoporosis	0.00208	0.00432	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CALCR—osteoporosis	0.00208	0.00432	CbGpPWpGaD
Fluocinonide—NR3C1—Transcription factor regulation in adipogenesis—TNF—osteoporosis	0.00206	0.00427	CbGpPWpGaD
Fluocinonide—Dizziness—Ethinyl Estradiol—osteoporosis	0.00204	0.00394	CcSEcCtD
Fluocinonide—Pruritus—Pamidronate—osteoporosis	0.00202	0.00391	CcSEcCtD
Fluocinonide—NR3C1—Adipogenesis—BMP2—osteoporosis	0.00201	0.00416	CbGpPWpGaD
Fluocinonide—Infection—Estradiol—osteoporosis	0.002	0.00387	CcSEcCtD
Fluocinonide—Dizziness—Risedronate—osteoporosis	0.00199	0.00385	CcSEcCtD
Fluocinonide—Nervous system disorder—Estradiol—osteoporosis	0.00197	0.00382	CcSEcCtD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—VDR—osteoporosis	0.00196	0.00406	CbGpPWpGaD
Fluocinonide—Skin disorder—Estradiol—osteoporosis	0.00196	0.00378	CcSEcCtD
Fluocinonide—Rash—Ethinyl Estradiol—osteoporosis	0.00195	0.00376	CcSEcCtD
Fluocinonide—Dermatitis—Ethinyl Estradiol—osteoporosis	0.00194	0.00376	CcSEcCtD
Fluocinonide—Headache—Ethinyl Estradiol—osteoporosis	0.00193	0.00374	CcSEcCtD
Fluocinonide—Hypersensitivity—Zoledronate—osteoporosis	0.00192	0.00372	CcSEcCtD
Fluocinonide—Rash—Risedronate—osteoporosis	0.0019	0.00367	CcSEcCtD
Fluocinonide—Dermatitis—Risedronate—osteoporosis	0.0019	0.00366	CcSEcCtD
Fluocinonide—Dizziness—Pamidronate—osteoporosis	0.00189	0.00366	CcSEcCtD
Fluocinonide—Headache—Risedronate—osteoporosis	0.00188	0.00364	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—PTH—osteoporosis	0.00185	0.00384	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.00185	0.00358	CcSEcCtD
Fluocinonide—Pruritus—Zoledronate—osteoporosis	0.00185	0.00357	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—CNR2—osteoporosis	0.00181	0.00374	CbGpPWpGaD
Fluocinonide—Rash—Pamidronate—osteoporosis	0.0018	0.00349	CcSEcCtD
Fluocinonide—Dermatitis—Pamidronate—osteoporosis	0.0018	0.00348	CcSEcCtD
Fluocinonide—Headache—Pamidronate—osteoporosis	0.00179	0.00346	CcSEcCtD
Fluocinonide—Pruritus—Conjugated Estrogens—osteoporosis	0.00178	0.00344	CcSEcCtD
Fluocinonide—Dizziness—Zoledronate—osteoporosis	0.00173	0.00334	CcSEcCtD
Fluocinonide—Pain—Estradiol—osteoporosis	0.00172	0.00333	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—WNT1—osteoporosis	0.0017	0.00352	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—ESR1—osteoporosis	0.00168	0.00349	CbGpPWpGaD
Fluocinonide—Dizziness—Conjugated Estrogens—osteoporosis	0.00166	0.00322	CcSEcCtD
Fluocinonide—NR3C1—Transcription factor regulation in adipogenesis—IL6—osteoporosis	0.00166	0.00344	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MGLL—osteoporosis	0.00166	0.00343	CbGpPWpGaD
Fluocinonide—Rash—Zoledronate—osteoporosis	0.00165	0.00318	CcSEcCtD
Fluocinonide—Dermatitis—Zoledronate—osteoporosis	0.00165	0.00318	CcSEcCtD
Fluocinonide—Headache—Zoledronate—osteoporosis	0.00164	0.00316	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—LRP5—osteoporosis	0.00162	0.00335	CbGpPWpGaD
Fluocinonide—Rash—Conjugated Estrogens—osteoporosis	0.00159	0.00307	CcSEcCtD
Fluocinonide—Dermatitis—Conjugated Estrogens—osteoporosis	0.00158	0.00306	CcSEcCtD
Fluocinonide—Headache—Conjugated Estrogens—osteoporosis	0.00158	0.00305	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	0.00155	0.00322	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	0.00155	0.00321	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—LRP6—osteoporosis	0.00155	0.0032	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—PTHLH—osteoporosis	0.00154	0.00318	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—osteoporosis	0.0015	0.00311	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Estradiol—osteoporosis	0.00148	0.00287	CcSEcCtD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—ESR2—osteoporosis	0.00146	0.00303	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	0.00145	0.003	CbGpPWpGaD
Fluocinonide—Pruritus—Estradiol—osteoporosis	0.00142	0.00275	CcSEcCtD
Fluocinonide—SMO—GPCR ligand binding—POMC—osteoporosis	0.00138	0.00286	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—CALCA—osteoporosis	0.00135	0.0028	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—POMC—osteoporosis	0.00134	0.00277	CbGpPWpGaD
Fluocinonide—Dizziness—Estradiol—osteoporosis	0.00133	0.00257	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—TLN1—osteoporosis	0.00131	0.0027	CbGpPWpGaD
Fluocinonide—Rash—Estradiol—osteoporosis	0.00127	0.00245	CcSEcCtD
Fluocinonide—Dermatitis—Estradiol—osteoporosis	0.00127	0.00245	CcSEcCtD
Fluocinonide—Headache—Estradiol—osteoporosis	0.00126	0.00244	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—P4HB—osteoporosis	0.00113	0.00233	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—IRS2—osteoporosis	0.0011	0.00228	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PTH—osteoporosis	0.0011	0.00227	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—RAP1A—osteoporosis	0.00108	0.00223	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—LEP—osteoporosis	0.00108	0.00223	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CNR2—osteoporosis	0.00107	0.00221	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—NFATC1—osteoporosis	0.00105	0.00218	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—DKK1—osteoporosis	0.00104	0.00216	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—WNT1—osteoporosis	0.001	0.00208	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—FGA—osteoporosis	0.000976	0.00202	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—ADCY5—osteoporosis	0.000962	0.00199	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—IRS1—osteoporosis	0.000959	0.00199	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PTHLH—osteoporosis	0.000907	0.00188	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—BMP2—osteoporosis	0.000907	0.00188	CbGpPWpGaD
Fluocinonide—NR3C1—Endoderm Differentiation—TGFB1—osteoporosis	0.000895	0.00185	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—IGF1—osteoporosis	0.000889	0.00184	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—FGB—osteoporosis	0.000888	0.00184	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—MYC—osteoporosis	0.000876	0.00182	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—TGFB1—osteoporosis	0.000874	0.00181	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PSMA2—osteoporosis	0.000857	0.00178	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PSMA5—osteoporosis	0.000857	0.00178	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CALCA—osteoporosis	0.000799	0.00165	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—osteoporosis	0.00078	0.00162	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—IL6R—osteoporosis	0.000779	0.00161	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—U2AF1—osteoporosis	0.000777	0.00161	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—KL—osteoporosis	0.000725	0.0015	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—POMC—osteoporosis	0.000708	0.00147	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—IL6R—osteoporosis	0.00069	0.00143	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—IL6—osteoporosis	0.000659	0.00136	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—ESR2—osteoporosis	0.000618	0.00128	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—IL1B—osteoporosis	0.000593	0.00123	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—IL6—osteoporosis	0.00058	0.0012	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—RPL24—osteoporosis	0.000577	0.0012	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ADCY5—osteoporosis	0.000568	0.00118	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—SPP1—osteoporosis	0.00055	0.00114	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—TGFB1—osteoporosis	0.000533	0.0011	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—TNF—osteoporosis	0.000498	0.00103	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IRS2—osteoporosis	0.000497	0.00103	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—VDR—osteoporosis	0.000491	0.00102	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—LEP—osteoporosis	0.000487	0.00101	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ESR1—osteoporosis	0.000465	0.000962	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IRS1—osteoporosis	0.000434	0.000899	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—TNF—osteoporosis	0.00043	0.000891	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—POMC—osteoporosis	0.000418	0.000866	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IL6R—osteoporosis	0.000408	0.000845	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IGF1—osteoporosis	0.000402	0.000833	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—IL6—osteoporosis	0.000401	0.000832	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—ESR1—osteoporosis	0.000375	0.000777	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—IL6—osteoporosis	0.000347	0.000719	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—PSMA2—osteoporosis	0.000333	0.00069	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—PSMA5—osteoporosis	0.000333	0.00069	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—IL6—osteoporosis	0.000307	0.000637	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—ESR2—osteoporosis	0.000298	0.000617	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MYC—osteoporosis	0.000242	0.000501	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TGFB1—osteoporosis	0.000241	0.000499	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—VDR—osteoporosis	0.000236	0.000489	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—MYC—osteoporosis	0.000195	0.000404	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IL6—osteoporosis	0.000182	0.000376	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—ESR1—osteoporosis	0.000181	0.000374	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—MYC—osteoporosis	9.39e-05	0.000195	CbGpPWpGaD
